Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20578148 | 1.00 | MAOB (0.49) | MAOBMAOASCN9ACYP2D6CYP2C9 | |
| SCHEMBL4851286 | 0.82 | HPGD (0.53) | ALDH1A1MEN1KMT2A | |
| SCHEMBL8996609 | 0.82 | SIGMAR1 (0.56) | CYP2D6CYP2C9CYP2C19RECQLALDH1A1 | |
| SCHEMBL8996599 | 0.82 | SIGMAR1 (0.56) | CYP2D6CYP2C9CYP2C19RECQLALDH1A1 | |
| SCHEMBL891954 | 0.82 | SIGMAR1 (0.56) | CYP2D6CYP2C9CYP2C19RECQLALDH1A1 | |
| SCHEMBL17604065 | 0.79 | MAOB (0.46) | MAOBMAOASCN9ACYP2D6ANPEP | |
| SCHEMBL4854236 | 0.78 | MEN1 (0.44) | MEN1KMT2A | |
| SCHEMBL16702357 | 0.77 | MEN1 (0.48) | ALDH1A1MEN1KMT2A | |
| SCHEMBL6237660 | 0.77 | MAOB (0.56) | MAOBMAOASCN9AANPEP | |
| SCHEMBL6513442 | 0.77 | MAOB (0.56) | MAOBMAOASCN9AANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3412665-B1 | SUVOREXANT INTERMEDIATES AND PREPARATION METHODS THEREOF | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2021-03-03 | — | — | EP | disclosed |
| US-10618891-B2 | Suvorexant intermediate and preparation method thereof | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2020-04-14 | — | — | US | disclosed |
| US-20190040052-A1 | SUVOREXANT INTERMEDIATE AND PREPARATION METHOD THEREOF | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2019-02-07 | — | — | US | disclosed |
| EP-3412665-A1 | SUVOREXANT INTERMEDIATE AND PREPARATION METHOD THEREOF | Zhejiang Huahai Pharmaceutical Co., Ltd (CN) | 2018-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040052-A1 | SUVOREXANT INTERMEDIATE AND PREPARATION METHOD THEREOF | COMT, KMO, CYP4B1 | MAOB 46/4885MAOA 155/4885SCN9A 1174/4885 |
| US-10618891-B2 | Suvorexant intermediate and preparation method thereof | COMT, KMO, CYP4B1 | MAOB 46/4885MAOA 155/4885SCN9A 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.